Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI ... MarketWatch The European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who ... |
